Valneva (NASDAQ:VALN) Issues Quarterly Earnings Results

Valneva (NASDAQ:VALNGet Rating) announced its earnings results on Thursday. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.38, reports. The business had revenue of $24.51 million for the quarter, compared to analyst estimates of $22.51 million.

VALN stock traded up $0.96 during midday trading on Friday, hitting $25.16. The company’s stock had a trading volume of 9,690 shares, compared to its average volume of 22,899. The firm has a 50-day simple moving average of $33.06 and a 200-day simple moving average of $40.65. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.25 and a current ratio of 1.59. Valneva has a 52-week low of $24.12 and a 52-week high of $67.84.

Separately, Zacks Investment Research raised shares of Valneva from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to, Valneva presently has an average rating of “Hold” and a consensus price target of $37.00.

A number of large investors have recently added to or reduced their stakes in VALN. Millennium Management LLC purchased a new position in Valneva in the second quarter valued at $259,000. Granite Point Capital Management L.P. purchased a new position in Valneva in the third quarter valued at $376,000. Morgan Stanley purchased a new position in Valneva in the third quarter valued at $97,000. Finally, Alps Advisors Inc. purchased a new position in Valneva in the fourth quarter valued at $3,369,000. Hedge funds and other institutional investors own 0.21% of the company’s stock.

Valneva Company Profile (Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Stories

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.